DD
Dr. Dmitrij Hristodorov
General Partner at Forbion
Munich, Bavaria
Overview
Dr. Dmitrij Hristodorov is currently the General Partner at Forbion in Munich, Bavaria, with a strong background in life sciences and extensive experience in business development. He has held leadership roles and served on the board of multiple biotechnology companies, showcasing his expertise in ophthalmology, immunology, and cancer research within the pharmaceutical industry.
Dr. Hristodorov's career highlights include his progression from Senior Associate to General Partner at Forbion, demonstrating his strategic leadership and investment acumen, as well as his involvement in various biotechnology companies as a board member, indicating his significant contributions to the growth and development of emerging life science ventures.
Work Experience
General Partner
2024 - Current
Partner
2021 - 2024
Principal
2021 - 2021
Senior Associate
2020 - 2020
Board Member
2024
Board Member
2024
Board Member
2022
Board Member
2023
Board Member
2022
New gene editing platform based on recombinases
Board Member
2022
Board Member
2021
Targeting RyR1/2 to treat cardiac, musculoskeletal and neurological diseases.
Board Member
2023 - 2025
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Raised $85,000,000.00 from HealthCap, RA Capital Management, Forbion Capital Partners and OrbiMed.
Board Member
2021 - 2024
One treatment a year. Life changing.
Education
Dr. rer. nat. (PhD)
2011 - 2013
Master of Science (MS)
2009 - 2011
Bachelor of Science (BS)
2006 - 2009
Abitur
1998 - 2005